OFIX

Orthofix Medical Inc.

7 filings tracked

healthcaremedical devicesSMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 5

Gross margin increased from 62.8% to 70.9% following the exit from M6 product lines.

margin expansion

80%

neutralMay 5

Drew down $65 million from delayed-draw term loan to increase liquidity.

capital raise

60%

bearishMay 5

Reported a net loss of $20.9 million for the first quarter.

earnings miss

70%

bearishMay 5

FDA reclassification of bone growth stimulators may increase competitive pressure.

regulatory action

50%

bullishMay 5

Gross margin increased from 62.8% to 70.9% following the exit from M6 product lines.

margin expansion

80%

neutralMay 5

Drew down $65 million from delayed-draw term loan to increase liquidity.

capital raise

60%

bearishMay 5

Reported a net loss of $20.9 million for the first quarter.

earnings miss

70%

bearishMay 5

FDA reclassification of bone growth stimulators may increase competitive pressure.

regulatory action

50%

bullishMay 5

Gross margin increased from 62.8% to 70.9% following the exit from M6 product lines.

margin expansion

80%

neutralMay 5

Drew down $65 million from delayed-draw term loan to increase liquidity.

capital raise

60%

bearishMay 5

Reported a net loss of $20.9 million for the first quarter.

earnings miss

70%

bearishMay 5

FDA reclassification of bone growth stimulators may increase competitive pressure.

regulatory action

50%

bullishMay 5

Gross margin increased from 62.8% to 70.9% following the exit from M6 product lines.

margin expansion

80%

neutralMay 5

Drew down $65 million from delayed-draw term loan to increase liquidity.

capital raise

60%

bearishMay 5

Reported a net loss of $20.9 million for the first quarter.

earnings miss

70%

bearishMay 5

FDA reclassification of bone growth stimulators may increase competitive pressure.

regulatory action

50%

bullishMay 5

Gross margin increased from 62.8% to 70.9% following the exit from M6 product lines.

margin expansion

80%

neutralMay 5

Drew down $65 million from delayed-draw term loan to increase liquidity.

capital raise

60%

bearishMay 5

Reported a net loss of $20.9 million for the first quarter.

earnings miss

70%

bearishMay 5

FDA reclassification of bone growth stimulators may increase competitive pressure.

regulatory action

50%

bullishMay 5

Gross margin increased from 62.8% to 70.9% following the exit from M6 product lines.

margin expansion

80%

neutralMay 5

Drew down $65 million from delayed-draw term loan to increase liquidity.

capital raise

60%

bearishMay 5

Reported a net loss of $20.9 million for the first quarter.

earnings miss

70%

bearishMay 5

FDA reclassification of bone growth stimulators may increase competitive pressure.

regulatory action

50%

bullishMay 5

Gross margin increased from 62.8% to 70.9% following the exit from M6 product lines.

margin expansion

80%

neutralMay 5

Drew down $65 million from delayed-draw term loan to increase liquidity.

capital raise

60%

bearishMay 5

Reported a net loss of $20.9 million for the first quarter.

earnings miss

70%

bearishMay 5

FDA reclassification of bone growth stimulators may increase competitive pressure.

regulatory action

50%

Filing History

10-QMay 5, 2026

The Q1 2026 filing reveals a company at a critical crossroads, balancing successful structural pruning against persistent financial fragility. The elimination of the M6 product line and the resulting margin expansion provide a positive signal that management is capable of making hard decisions to protect the bottom line. However, the reliance on a $65 million delayed-draw loan to boost cash reserves suggests that the company is not yet generating sufficient organic cash flow to fund its operations and settle legacy legal disputes. Investors are now faced with a trade-off between the company's improving operational efficiency and its high debt-to-EBITDA ratio. While the core segments show steady demand and the distributor transition is yielding results, the looming threat of increased competition due to FDA reclassification and the drain of executive litigation settlements create a volatile environment. The overall impact of the filing is a cautious optimism regarding the business model, tempered by significant concerns regarding the balance sheet and external regulatory risks.